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Nanoparticles and bacteria can be used, independently, to deliver genes and proteins into mammalian cells for monitoring or altering
gene expression and protein production. Here, we show the simultaneous use of nanoparticles and bacteria to deliver DNA-based
model drug molecules in vivo and in vitro. In our approach, cargo (in this case, a fluorescent or a bioluminescent gene) is loaded
onto the nanoparticles, which are carried on the bacteria surface. When incubated with cells, the cargo-carrying bacteria
(‘microbots’) were internalized by the cells, and the genes released from the nanoparticles were expressed in the cells. Mice
injected with microbots also successfully expressed the genes as seen by the luminescence in different organs. This new approach
may be used to deliver different types of cargo into live animals and a variety of cells in culture without the need for complicated
genetic manipulations.
One of the most significant challenges facing the treatment
of diseases is early intervention to deliver specific therapeutic
cargo efficiently into cells to alter gene expression and
subsequent protein production. Recent advances in
nanotechnology have been used to deliver such cargoes into
single cells through the use of nanoparticles for imaging1–3,
diagnostics4,5 and therapeutics6–8. Although significant advances
have been made, many difficulties remain in delivering the
nanoparticles to the tumour sites, mainly because of the physical
barriers encountered in solid tumours, such as malformed blood
supplies, elevated interstitial pressure, and large transport
distances in the tumour interstitium9,10.
Bacteria have been used as a non-viral means to transfer
plasmid DNA into mammalian cells through a process called
‘bactofection’ (reviewed in ref. 11). Several intracellular bacteria,
including Listeria monocytogenes, which is responsible for food-
borne infections in humans and animals12, can penetrate
mammalian cells that are normally non-phagocytic. These
bacteria need specific surface molecules that interact with host-
cell receptors for this invasion step13–15 once inside the cells, the
bacteria carriers are disrupted—by treatment with antibiotics—
and the DNA is released. L. monocytogenes-based bactofection
systems have shown efficient transfer of genetic material inside
the cells16,17. Other earlier reports include use of attenuated
(reduced infectivity) bacteria such as Shigella18 and Salmonella
typhimurium19,20 for the delivery of DNA-based vaccines. Bacteria
themselves have additional advantages as delivery systems. For
example, attenuated strains of Escherichia coli, S. typhimurium,
Vibrio cholerae and L. monocytogenes have been shown to be
capable of multiplying selectively in tumours21, and in the case of
Clostridium and Bifidobacterium spp., they even inhibit tumour
growth20,22. Some of the unique properties of attenuated Listeria
strains make them an ideal non-viral gene delivery vehicle23 – 25. It
should also be noted that antibiotics can control bacterial
replication in the body or activate gene-based therapeutic
molecules, as in the case with tetracycline-regulated control of
gene expression26.
Here, we report a novel technique for delivery of nanoparticles
into cells, which takes advantage of the invasive properties of
bacteria. The gene or cargo is not carried inside the bacteria, but
rather remains on the surface conjugated to nanoparticles.
Hence, our approach does not require bacterial disruption for
delivery, or any genetic engineering of the bacteria for different
cargo. Although more than one gene can be delivered by means
of bactofection, many more copies of a target cargo can be
carried with one bacterium using the method described here. We
also show that nucleic acid-based model drugs (plasmid DNAs
coding for green fluorescence protein (GFP), luciferase and
secreted alkaline phosphatase (SEAP)) loaded on the
nanoparticles can be released from the carriers and eventually
find their way into the nucleus, with subsequent transcription
and translation of their respective proteins, for both in vitro and
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Figure 1 Bacteria-mediated delivery of nanoparticles and cargo. a, Docking of bacteria with functionalized multiple-sized nanoparticles through biotinylated
antibodies and surface–antigen interactions (microbots). Streptavidin-coated nanoparticles can carry biotinylated cargo. b, Delivery of intervention agents using
microbots. c–k, Assembled microbots with their cargos: bacteria (blue) (c), streptavidin-coated 40-nm fluorescent-red nanoparticles (d), neutravidin-coated
200-nm fluorescent-green nanoparticles (e). f–h, Overlays of images c and e (f), images d and e (g), and images c–e (h). i, Profiles of lines G and R from g.
j, Simulated height image. k, SEM images of microbots (arrows show nanoparticles).
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in vivo conditions. Such bacteria, which we call ‘microbots’, can
potentially be used to carry proteins, small molecules and even
synthetic objects like sensors and therapeutic moieties into
different types of cells.
MICROBOTS DELIVER NANOPARTICLES AND DNA INTO CELLS
Our approach for preparing the microbots uses biotinylated
monoclonal antibody C11E927,28 against a surface protein,
N-acetylmuramidase29, on L. monocytogenes bacteria to attach
streptavidin-coated polystyrene nanoparticles onto the bacterial
surface. Biotinylated GFP plasmid was then attached to the
remaining streptavidin sites on the nanoparticles (Fig. 1a) (see
Methods). This generalized approach can be used to attach
particles of various sizes or different entities onto Listeria to be
delivered into eukaryotic cells (Fig. 1b). We characterized the
attachment of the particles on individual bacteria with
fluorescence imaging (Fig. 1c–j) and scanning electron
microscopy (SEM) (Fig. 1k). Fluorescence images of biotinylated
antibody-covered Listeria incubated with streptavidin-coated
40 nm (red) and 200 nm (green) nanoparticles clearly show that
the bacterium, which was stained blue, is co-localizing with the
40-nm Texas red-labelled nanoparticles and 200-nm FITC green-
labelled nanoparticles (Fig. 1c–j), thus proving that the same
bacteria can carry different size particles.
When fluorescently labelled bacteria were incubated with KB
(human nasopharyngeal carcinoma) cells for up to 3 h at 37 8C,
bacteria entered the cytosol of the cells and resulted in significant
bacterial replication in the cells (see Supplementary Information,
Fig. S1 and video). Incubation of the cells with the biotinylated
anti-L. monocytogenes monoclonal antibody did not neutralize
the infectivity of the microbots (see Supplementary Information,
Table S1). We next attempted to deliver nanoparticles docked on
the bacterial cell surface as described in the Methods. The
200-nm particles on their own were not internalized by the cells
within the 3 h period, but rather were associated with the cell
surface (Fig. 2a), as also verified by fluorescence imaging
(Fig. 2b), whereas microbots successfully delivered the 200-nm
particles inside the KB cells when incubated for 3 h (Fig. 2c). The
nanoparticles were found in subcellular vesicle compartments and
were also free in the cytosol. The yellow co-localization signal in
the images (Fig. 2c) was due to red-labelled cellular membranes
and green nanoparticles. Optical confocal slices proved that green
fluorescent-labelled particles were indeed inside the cells and not
on the cell surface (Fig. 2d) and approximately twenty 200-nm
particles (on average) entered the cells when transported with the
microbots (Fig. 2e).
Detailed flow cytometry analysis was also performed with
partial cell lysis and secondary antibody immunostaining to
prove and characterize the uptake of the nanoparticles mediated
by the bacteria (Fig. 3a–d). As expected, the secondary anti-
mouse antibody did not enter the cells to stain the monoclonal
antibody C11E9 that was delivered into the cells by means of
microbots (Fig. 3a) until the cells were lysed by a mild detergent
treatment. The cells (lower left quadrants in Fig. 3b,c) were
incubated separately with streptavidin-coated 200-nm particles
(upper left quadrants in Fig. 3b,c), L. monocytogenes only (lower
right quadrants in Fig. 3b,c) and microbots with streptavidin-
coated 200-nm particles (upper right quadrants in Fig. 3b,c). After
removal of the non-cell-associated material, the samples were
either left untreated (Fig. 3b) or lysed with Triton-X100 (Fig. 3c).
Subsequently, all samples were stained with a phycoerythrin
(PE)-conjugated monoclonal antibody against mouse IgG and
were subjected to flow cytometry analysis using dual channels for
fluorescein isothiocyanate (FITC) (FL1) and PE (FL4). An analysis
of the results of the PE readings (Fig. 3b,c) revealed that
approximately 27% of the total PE signal (42%) was derived from
intracellular sources, that is, from microbots (Fig. 3d).
Approximately 15% of the total PE signal was either extracellular
or cell membrane associated. Cells alone or KB cells with Listeria
only samples did not have significant PE signals (Fig. 3d).
Microbots, docked with the model nucleic acid-based
therapeutic GFP DNA, delivered the gene to the nucleus
successfully, resulting in the expression of GFP as diffuse green
fluorescence in the cytoplasm of KB cells (Fig. 4). Although the
nanoparticles were intracellular at both 3 h (Fig. 4a) and 18 h
(Fig. 4b) time points, the expression of GFP occurred at 18 h
post-delivery (Fig. 4b,c). Dissociation of the nanoparticles from
bacteria and the docked DNA from the nanoparticles may be
facilitated by the low pH environment of the lysosomal
compartments (Fig. 4d). Image analysis revealed a transfection
efficiency of approximately 41.7+8.8% (Fig. 4b,c; see also
Supplementary Information, Fig. S5). The efficiency of
bactofection has been reported to range from 2 to 20%
(ref. 16). In three of the four tested cell lines (Caco2, COS-1,
HeLa, HepG2), the efficiency was extrapolated to be less than
10% for the same study. We believe that the higher transfection
efficiency using our approach is due to both nanoparticle
properties (their high surface-to-volume ratio, which allows more
cargo to be loaded) and the number of nanoparticles that can be
docked onto the bacterial surface.
CYTOTOXICITY OF MICROBOTS
We examined the cellular cytotoxic response to 40-nm and 200-nm
streptavidin-coated fluorescent polystyrene nanoparticles and to
bacteria with nanoparticles in four cell lines from human solid-
organ tumours (MCF-7, KB, HeLa, HepG-2). All cells rapidly
responded to the nanoparticles within 1 h with acute lactate
dehydrogenase (LDH) release, but their response gradually
decreased (see Supplementary Information, Fig. S7). When
compared with detergent-damaged positive control samples, all
cells incubated with 40-nm particles alone showed up to 60%
cytotoxicity within 1 h. Over three days this response gradually
decreased to 14% and cells were dividing, indicating that they
were metabolically active. Neither Listeria nor microbots with
nanoparticles caused a drastic cellular cytotoxic response; the
response was less than for the particles alone. These samples had
less than approximately 20% of the cytotoxicity of the detergent-
lysed cells, except for the L. monocytogenes sample with the
HepG-2 cell line, which had a cytotoxic response of 40% (see
Supplementary Information, Fig. S7b). Although the microbots
had nanoparticles attached to them, the cells seemed to release
more LDH for the nanoparticle-only samples. The 40-nm
particles had higher cytotoxicity than the 200-nm particles
because they can be taken up by the cells freely whereas the
200-nm particles are internalized only with the aid of microbots
(Fig. 2). Invasion assays were also performed (see Supplementary
Information, Fig. S7c) to evaluate the invasion efficiency of
L. monocytogenes, L. innocua and the microbots for the four cell
lines used in the study. The highest invasion was seen for the
HepG-2 cells with L. monocytogenes.
GENE DELIVERY AND PROTEIN EXPRESSION IN MICE
Mice were injected intraperitoneally with microbots carrying
the firefly luciferase gene on the 40-nm particle surface. Whole
animal bioluminescence images (Fig. 5) showed that 3 days
after infection, microbots successfully delivered the gene into
the mice organs. The luciferase plasmid DNA was able to enter
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the nucleus and express the luciferase protein in the animals
(Fig. 5a). There was no significant detectable endogenous
luciferase activity in the animals injected with PBS as a control
at 3 days post-injection (mean value 5 a.u., s.d. ¼ 9.4, n ¼ 4).
Although all microbot-treated mice expressed the luciferase
gene at a level of 380-fold (3.81  104%) more than the
controls, the level of expression was highly variable in each
animal (mean value 1,908 a.u., s.d. ¼ 1,451, n ¼ 3), as
indicated by the photon counts per square pixel area of the
expression regions from Fig. 5a (see also Fig. 5b). We were also
able to elucidate the location of the fluorescent nanoparticles
using a fluorescence illumination and background elimination
setup (described in the Supplementary Information, Methods),
which enabled us to co-localize nanoparticle locations (Fig. 6a)
and luciferase expression. The luciferase activity was seen
throughout the internal organs, but seemed to localize in
kidney, liver/pancreas, intestine, spleen, pericardium and lungs
(in order of decreasing signal strength; Figs 5a and 6b–d). As
is clearly evident in Fig. 6, the majority of the luciferase
expression was localized in an area including the liver, pancreas,
duodenum, spleen and kidneys. The kidneys had
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Figure 2 Internalization of microbots and their cargos. a, Time-dependent nonspecific association of 200-nm particles alone with KB cells. b,c, Fluorescence
microscope images of cells incubated for 3 h with b, 200-nm particles alone (scale bar¼10mm) and c, with microbots. d, Confocal microscope sections of a cell
treated as in c, showing internalization. e, Average number of internalized nanoparticles per cell as calculated from panels b–d (NP, nanoparticle alone; mBot,
with microbots). Cell membranes are red, nuclei are blue and nanoparticles are green in b–d. Yellow indicates internalization in c. Error bars represent
standard deviations.
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An alternative enzymatic method further verified the
bioluminescence findings and quantified the microbot-mediated
delivery and expression of the genes. Mice were injected with
microbots carrying luciferase and SEAP gene cargoes and
negative PBS-only controls. Three days later, select organs (liver,
kidneys, spleen and intestines) were collected aseptically,
enzymatically digested into homogenates and the expression of
the reporter genes were quantified luminometrically (for
luciferase) and chemiluminometrically (for SEAP). The luciferase
assay had a signal half-life of 30 min, and, in preliminary assays,
less than 5% signal intensity decay was observed within the
reading time frame of the assays. In the luciferase and SEAP
detection assay systems used, reporters yield linear assays with
attomole sensitivities and no endogenous activity is associated
with these reporters. Some intrinsic alkaline phosphatase activity
can be found in various organs, but, being heat-labile, this
enzyme is inactivated by treatment at 65 8C for 30 min, as was
done here. Both luciferase (Fig. 6d) and SEAP (Fig. 6e) cargo
molecules were delivered to the internal organs of live mice.
Expressions of both reporter genes were highest in the intestinal
tissue, which is also a natural target organ for L. monocytogenes.
Kidney and liver samples from microbot-treated mice had
noticeable amounts of luciferase and SEAP protein activity.
Although not tested, the bioluminescence images showed
noticeable levels of luciferase activity in the gall bladder, lungs
and heart as well. Luciferase expression levels in the homogenates
of the tested organs were highly variable, evident from the large
standard deviations in the luciferase enzymatic activity (Fig. 6d).
This could be due to variability in the efficiency of the SV40
promoter driving the luciferase gene in different tissues. The level
of SEAP enzyme activity was more uniform in the tested organs
(Fig. 6e). L. monocytogenes, injected via the intraperitoneal
route can disseminate into the internal organs of mice, with a
majority of the bacteria are found in the liver, spleen, kidneys,
peripheral blood mononuclear cells and central nervous
system30,31. In line with these previous reports, in our study, the
bioluminescence due to luciferase activity was also localized in
the liver, pancreas, duodenum, spleen and kidneys. Some
activity in the intestine, lungs and heart was also seen at









































KB cells with 200 nm & microbots, before lysis
KB cells with 200 nm & microbots, after lysis
Nanoparticle Microbot
into KB cell
KB cell  KB + LM
Quad Events % Events XMean YMean
UL 1289 28.00 95.6 19.6
UR 724 15.70 227.3 39.3
LL 2571 55.80 51.7 5.6








Quad Events % Events XMean YMean
UL 116 2.30 105.6 19
UR 102 2.00 236.3 42.2
LL 4,806 93.90 71.8 3
LR 92 1.80 197.2 5.7
Figure 3 Flow-cytometric assessment of microbot uptake by cells. a, Evaluating the delivery of 200-nm particles into KB cells (red line) by flow cytometry.
Treated cells were stained with phycoerythrin (PE)-labelled anti-mouse IgG antibodies before (blue line) and after (green line) cell lysis. Quantifying the internalization
of b, nanoparticles alone and c, microbots. Quadrants in b and c: lower left (LL), KB cells; upper left (UL), 200-nm particles; lower right (LR), L. monocytogenes (LM)
alone; upper right (UR), microbots with 200-nm particles; d, Evaluating the location of nanoparticles (NPs) with and without microbots. PE-labelled secondary
antibody can access the interior of the cells only after cell lysis.
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by others32. Signals seen around the lower thorax of the animals
originate from the gall bladder, and this also has been well
documented previously32.
EFFICIENCY OF MICROBOT LOADING AND DELIVERY
From the confocal imaging studies, we found that each cell had
approximately 22 200-nm particles (see Supplementary
Information, Fig. S6). Because each microbot was carrying 1–3
particles, each human cell line used would therefore have at least
7–22 microbots. Previous immuno-electron microscopic analysis
revealed a uniform distribution of C11E9 on the surface of
L. monocytogenes cells, and the average number of C11E9-reactive
antigens was approximately 190 per bacterium25; hence, it is
reasonable to expect that a similar number of nanoparticles
could be docked on each bacterial cell surface. The SEM
images of the microbots (Fig. 1k) show that there are many
40-nm nanoparticles on the bacterial cell surface, supporting
the previous findings that the cell surface receptors
(N-acetylmuramidase) for antibody-C11E9 were uniformly
distributed. This finding may also explain why microbots were
fluorescing red in confocal and fluorescent microscopic images.
The observed fewer numbers of 200-nm particles docked onto
the bacterial cell surface may be due to steric hindrance, diffusion
limitations or other physical barriers that preclude access or
docking of 200-nm particles on the bacteria. Each 40-nm particle
has a biotin-binding capacity of 100, but for each 200-nm
particle this value is 2  104 (from the certificate of analysis
sheets of their manufacturer). Hence, each microbot is expected
to carry biotinylated-DNA molecules in this range into target
cells. The final spatial and temporal distribution of the microbots
in vivo is determined by the invasion ability of L. monocytogenes
for different tissue types and also by the filtration and
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10 µm
Figure 4 Intracellular delivery and expression of a model gene by microbots. a, Delivery of a plasmid DNA (coding for GFP) into KB cells using microbots at 3 h
post-incubation. The cell membranes are red, nuclei are stained blue, and yellow indicates intracellular co-localization due to red (cells) and green (200-nm particles)
signal overlap. b, A fluorescent micrograph (blue and green channels) of the sample in a at 18 h post-incubation. c, Expression of GFP from microbot-delivered DNA
at a higher magnification (1,000) at 18 h post-incubation. d, Disassociation of nanoparticles from the microbot surface at pH 4 and 7. Error bars represent
standard deviations.
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and lymphatic circulation system by different organs, in
varying degrees.
DISCUSSION
In this study, we have demonstrated the bacteria-mediated delivery
and visualization of different sized nanoparticles loaded with
functional nucleic acid molecules into non-phagocytic
mammalian cells of human solid organ tumours, and the
successful expression of the cargo plasmid DNA (GFP) from the
delivered nanoparticles. Liposomal or other encapsulated delivery
methods suffer from the problem of entrapment in the
subcellular vesicles and the biomolecule’s inability to access the
cytosol or other intended target sites such as the nucleus33–36. It
is well known that L. monocytogenes can escape from the
intracellular vesicles by means of the pore-forming activity of
listeriolysin O. During this process the therapeutic molecules can
diffuse into the cytoplasmic compartments. In a different
approach reported earlier, L. monocytogenes was used to deliver
DNA into the cytosol of mammalian cells by phage lysine
mediated partial self-destruction of the carrier bacteria and by
enhanced bacterial lysis due to the release of the intrinsically
synthesized phage lysine16.
Unlike these previously reported techniques, our approach
is simple and versatile. Nanoparticles can be acquired
commercially from various vendors, and have different surface
functionalities, and different material and optical properties.
Anchorage of the nanoparticles on the bacterial surface can easily
be achieved using biotinylated antibodies, which serve as docking
molecules through a streptavidin linkage. The ‘nanovehicles’ are
linked to the bacteria by means of an antigen–antibody
interaction, and the cargo and the bacteria can readily separate in
the lower pH environment of the subcellular compartments, as
made evident by the control experiments (Fig. 4d). Other factors,
such as intracellular enzymatic processing or destabilization of
antigen–antibody binding or a reduction in the biotin–
streptavidin interactions can also be involved in the release
mechanisms of the DNA, and all of these possibilities can
potentially be used for endowing microbots with smart cargo
release ability. Also, the use of intracellular bacteria in general
and Listeria in particular for the delivery of nanoscale
therapeutics has many advantages. Listeria bacteria have been
shown to penetrate and colonize solid organ tumours19,37 to
which drugs circulating in the bloodstream have limited
accessibility. Other nanoparticle-only based drug delivery
approaches38 still require the nanoparticles to be brought close to
the tumour site, which is especially problematic in solid organ
tumours and regions lacking vascularization.
In conclusion, microbots successfully delivered their cargos of
nucleic acid-based model drugs, plasmid DNAs for firefly
luciferase and SEAP enzymes into multiple organs of live mice,
and the delivered genes also resulted in functional protein
expression by three days post-treatment. As we have seen in the
in vitro GFP expression assays, the delivered plasmid DNAs
were able to escape from intracellular entrapment and were
targeted to the nuclei of the cells, resulting in transcription and
expression of the enzymes. Hence, this novel technology can be
used to deliver these reporter molecules for whole-animal live
imaging agents (luciferase) or for non-invasive in vivo reporter
assays (SEAP). Our future studies will concentrate on the
development of an attenuated Listeria strain, microbot-mediated
delivery of artificial biohybrid nanostructures, delivery of larger
size particles and functional proteins, and investigation of solid
organ tumour penetration by microbots for applications in
diagnostics and therapy at the single cell level and up to a few
cells. Our bacteria-mediated nanoparticle and cargo delivery
approach, which we term microbotics, promises excellent
potential for nonviral gene delivery, and unique capabilities for
biomedical nanorobotics and nanomedical therapy.
METHODS
PREPARATION OF MICROBOTS
Bacteria (108 colony forming units (c.f.u.) per ml, 1 ml) were incubated with a





























Figure 5 Microbot-mediated delivery and functional expression of
luciferase gene in mice. a, In mice whole-animal bioluminescence images of
mice with microbots carrying the firefly luciferase gene at three days post
microbot treatment. Note the significant increase in photons collected from the
microbot-treated animals (4–6) compared with the PBS-treated (sham-control)
animals (1–3). The mice are in the ventro-dorsal position. b, Quantification of
bioluminescence in sham-treated (white bar) and microbot-treated (blue bar)
mice from a. On average, an 380-fold increase in bioluminescence was
observed in microbot-treated animals compared with PBS-treated mice (n ¼ 3
animals per group, P , 0.01). Error bars represent standard deviations.
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After antibody attachment to the bacteria surface, two washes (see
Supplementary Information) were performed to remove unreacted antibody.
Streptavidin- or neutravidin-coated nanoparticles were then added
(1 1010 ml21) and the mixture was incubated at room temperature for 15 min,
at which time two low-speed washes were performed, and a centrifugal force
of 3,000 g was applied for 5 min to preferentially spin down the bacteria, but
not the nanoparticles. Microbots were diluted into PBS at 105 c.f.u. ml21 and
used immediately (or stored at 4 8C for no more than a week for SEM
imaging studies). A biotinylated and rhodamine-labelled plasmid DNA vector
encoding GFP under the control of a cytomegalovirus promoter (Gene
Therapy Systems) was used as the model nucleic acid therapeutic molecule
and was docked on the nanoparticle surfaces by streptavidin– or neutravidin–
biotin interaction (see Supplementary Information, Methods, for details).
IMMUNOFLUORESCENCE ANALYSIS OF INTRACELLULAR AND EXTRACELLULAR MICROBOTS
After the initial infection process, cell monolayers were rinsed twice with PBS to
remove unattached microbots and extra nanoparticles. Cells were trypsinized
and recovered from the culture chambers, spun down at 300 g for 5 min and
rinsed with Dulbecco’s phosphate buffered saline (D-PBS) solution (Sigma) by
performing a low-speed centrifugation as above. The cells were mounted on
microscope slides and observed with a fluorescence microscope equipped with
filters appropriate for FITC, Texas red and DAPI, and imaged using a cooled-
colour CCD camera. Bacterial DNA was labelled with Hoechst-33342 stain for
15 min at room temperature. During some studies bacteria were also dual
labelled with a lipophilic green-fluorescent cyanine-dye (DiO, Molecular Probes)
and Hoechst stain.
FLOW CYTOMETRIC ASSESSMENT OF NANOPARTICLE UPTAKE
Tumour cells were grown in 24-well tissue culture plates to 70% confluence
and were rinsed with the fresh media. Either 40-nm or 200-nm nanoparticles
were diluted in 10 ml of 1X Phosphate-Buffered Saline (PBS) to a final dilution of
0.01% (109 particles) and were added to the wells of the tissue culture plate.
The plates were returned back to the culture incubator and placed on a gently
rotating stirrer for 0.5 h, 1 h, 2 h, 3 h and 3 days. To obtain cells in suspension,
the cells were treated with 0.17% trypsin 20.02% EDTA (Sigma) at 37 8C for
1–3 min. Equal volumes of fresh medium were added to slow the digestion,
and the cells were centrifuged at 300 g for 5 min. The supernatant was
removed and the cells were washed once with wash buffer (PBS with 2% fetal
bovine serum) as above. Finally, the cells were resuspended in the growth
medium lacking serum and kept at 4 8C in an ice bath before being read in the
flow cytometer. Each sample was assayed by flow cytometry (Epics XL, Coulter),
and the data were analysed by both WinMDI and CellQuest software packages.
To differentiate intracellular and extracellular microbots by fluorescence
microscopy and flow cytometry, a dual-antibody staining procedure was used


































Figure 6 Characterization of in vivo protein expression. a, Live animal image of a mouse with microbots carrying the luciferase gene at three days post-injection.
Locations of the nanoparticles were assessed by imaging (480 nm excitation, 523 nm band-pass emission-filter and 5 min exposure). b, A bioluminescence image of
a with 35 min photon collection and integration. c, Anatomical localization of bioluminescence. A pseudo-coloured image of b was superimposed on a graphical
anatomical image of a mouse to illustrate anatomical localizations of the signals. Mice are positioned ventro-dorsal in a and dorso-ventral in b–c. d, Enzymatic
quantification of luciferase expression in organs of mice at three days post-injection. e, Enzymatic quantification of SEAP expression in organs of mice at three days
post-injection (in relative light units, RLU). Error bars represent standard deviations.
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IN VIVO EXPRESSION STUDIES
Microbots were prepared as described above, except two different biotinylated
plasmid DNAs coding for luciferase and SEAP were used instead of GFP40. The
concentration of plasmid DNA per 100 ml of injection-ready microbot
preparation was 5 mg DNA per 106 c.f.u. ml21 of microbots, which were
composed of 40-nm streptavidin-labelled Texas-red conjugated nanoparticles
(1011 particles ml21) anchored on L. monocytogenes by means of monoclonal
antibody C11E9. For analysis of in vivo delivery and expression, athymic
(immunodeficient) nude mice (Nu2Nu2, all 5- to 6-week-old males, Harlan
Sprague Dawley) were used throughout the studies as described in the
Supplementary Information, Methods.
BIOLUMINESCENCE IMAGING
In vivo bioluminescence imaging was performed using a protocol detailed
previously20 using a Kodak Image Station and its acquisition and analysis
software (Kodak). Additional image processing and quantifications were
performed using ImageJ software (W. Rasband, National Institute of Health) as
described in the Supplementary Information, Methods.
ENZYMATIC QUANTIFICATION ASSAYS FOR LUCIFERASE AND SEAP EXPRESSION
Organs (liver, kidneys, spleen and a small portion of the small intestine) from
killed microbot-treated and untreated animals were collected aseptically into
sterile plastic tubes and all subsequent sample processing was done on ice in
these containers. All of the organs were homogenized separately in 200 ml
reporter lysis buffer (Promega) on ice, centrifuged at 12,000 g for 1 min, and the
supernatants were divided into two equal-sized aliquots and immediately used in
the luciferase or SEAP assays, on the same day. For quantification of expression of
luciferase, a kit-based assay in 96-well format (Promega) was used according to
the instructions of the manufacturer of the kit.
ADDITIONAL METHODS
Additional details on the cell culture, invasion assays, nanoparticles, cytotoxicity
assay, flow cytometry, confocal and bioluminescence imaging and analysis and
enzymatic quantification of firefly luciferase and SEAP are available in the
Supplementary Information.
Received 8 February 2007; accepted 2 May 2007; published 10 June 2007.
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